Why healthcare AI models can only be as good as the data they’re trained on

The latest stories trending on MedCity News.

Editor's Pick

Top Story 'Garbage In Is Garbage Out': Why Healthcare AI Models Can Only Be As Good As The Data They're Trained On When developing or deploying new algorithms, hospitals and healthcare AI developers must pay close attention to the quality of training datasets, as well as take active steps to mitigate biases, said Divya Pathak, chief data officer at NYC Health + Hospitals, during a recent panel discussion.

Featured News

Share Your Insights on the Changing Healthcare Landscape Do you advise self-insured employers? Your insights will offer leading, innovative points of view that can guide employers and peers. Join us for this year's survey! FDA Clears the First Digital Therapeutic for Depression, But Will Payers Cover It? The Otsuka Pharmaceutical and Click Therapeutics mobile app Rejoyn received FDA clearance for use as an adjunct to medication in the treatment of major depressive disorder. But Otsuka must overcome hurdles facing digital therapeutics products, which have yet to gain traction among payers. Healthcare Docket: The Telehealth Boom is Inciting Action by Lawmakers and Fraudsters Alike Ever since the Covid-19 pandemic pushed telehealth to the forefront of American healthcare modalities, the genie has emerged from the lamp to quite a mixed crowd of cheerleaders and cheaters. Health Execs Applaud Biden's Final Rule on 'Junk' Health Insurance The American Medical Association, the Association for Community Affiliated Plans and several other organizations came out in support of the Biden administration's new rule on short-term health plans. The rule limits the plans to shorter time periods and requires them to be clearer about what they do and do not cover. 'Garbage In Is Garbage Out': Why Healthcare AI Models Can Only Be As Good As The Data They're Trained On When developing or deploying new algorithms, hospitals and healthcare AI developers must pay close attention to the quality of training datasets, as well as take active steps to mitigate biases, said Divya Pathak, chief data officer at NYC Health + Hospitals, during a recent panel discussion. AstraZeneca's Rare Disease Pipeline Notches Another FDA Approval The FDA approved AstraZeneca drug Voydeya as an add-on to standard therapies for paroxysmal nocturnal hemoglobinuria, a rare blood disorder. Alexion, now AstraZeneca's rare disease subsidiary, added the small molecule to its pipeline via a 2019 acquisition.

Resources

The Everybody Covered Campaign In this episode of MedCity FemFwd, we're joined by Millicent Gorham, CEO of the Alliance for Women's Health and Prevention (AWHP). AWHP recently launched the EveryBODY Covered campaign, which is advocating for comprehensive coverage of obesity care. Gorham discusses the current state of obesity treatment for women and her goals for the campaign. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe